ECSP045291A - Preparación de ácido n1-(2'-piridil)-1,2-propanodiamino sulfámico y su uso en la síntesis de piperazinas biológicamente activas - Google Patents
Preparación de ácido n1-(2'-piridil)-1,2-propanodiamino sulfámico y su uso en la síntesis de piperazinas biológicamente activasInfo
- Publication number
- ECSP045291A ECSP045291A EC2004005291A ECSP045291A ECSP045291A EC SP045291 A ECSP045291 A EC SP045291A EC 2004005291 A EC2004005291 A EC 2004005291A EC SP045291 A ECSP045291 A EC SP045291A EC SP045291 A ECSP045291 A EC SP045291A
- Authority
- EC
- Ecuador
- Prior art keywords
- preparation
- propanodiamine
- piridil
- sulphamic
- synthesis
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 3
- 150000004885 piperazines Chemical class 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 abstract 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Un proceso para la preparación de ácido N1-(2'-piridil)-1,2-alcanodiamino sulfámico de la fórmula (II) mediante la reacción de un compuesto de la fórmula (I) con NH2R', donde R y R', se definen en la especificación. El invento también incluye el compuesto de la fórmula (II) y los isómeros ópticos del mismo. El compuesto de la fórmula (II) es un agente intermedio útil para la preparación de derivados quirales de piperazina que son activos en el receptor de 5-HT1A.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36345702P | 2002-03-12 | 2002-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP045291A true ECSP045291A (es) | 2004-10-26 |
Family
ID=28041771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2004005291A ECSP045291A (es) | 2002-03-12 | 2004-09-10 | Preparación de ácido n1-(2'-piridil)-1,2-propanodiamino sulfámico y su uso en la síntesis de piperazinas biológicamente activas |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6784294B2 (es) |
| EP (2) | EP1483243B1 (es) |
| JP (1) | JP4397693B2 (es) |
| KR (1) | KR20040091720A (es) |
| CN (1) | CN100341854C (es) |
| AR (1) | AR038932A1 (es) |
| AT (2) | ATE360002T1 (es) |
| AU (1) | AU2003220122A1 (es) |
| BR (1) | BR0308315A (es) |
| CA (1) | CA2477886A1 (es) |
| CY (1) | CY1106677T1 (es) |
| DE (2) | DE60330199D1 (es) |
| DK (1) | DK1483243T3 (es) |
| EC (1) | ECSP045291A (es) |
| ES (2) | ES2334836T3 (es) |
| IL (1) | IL163829A0 (es) |
| MX (1) | MXPA04008731A (es) |
| NO (1) | NO20044049L (es) |
| NZ (1) | NZ535170A (es) |
| PT (1) | PT1483243E (es) |
| RU (1) | RU2314294C2 (es) |
| SI (1) | SI1483243T1 (es) |
| TW (1) | TWI288642B (es) |
| UA (1) | UA80272C2 (es) |
| WO (1) | WO2003078396A1 (es) |
| ZA (1) | ZA200408213B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060223824A1 (en) * | 2000-11-28 | 2006-10-05 | Wyeth | Serotonergic agents |
| ES2323451T7 (es) | 2001-07-20 | 2011-08-01 | Psychogenics Inc. | Tratamiento para el trastorno de hiperactividad con deficit de atencion. |
| US7361773B2 (en) * | 2002-03-12 | 2008-04-22 | Wyeth | Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines |
| JP4397693B2 (ja) | 2002-03-12 | 2010-01-13 | ワイス | Ｎ１−（２’−ピリジル）−１，２−アルカンジアミンスルファミン酸の合成および生物学的に活性なピペラジンの合成におけるその使用 |
| BR0308347A (pt) * | 2002-03-12 | 2005-01-25 | Wyeth Corp | Processo para fabricação de piperazinas 1,4-dissubstituìdas quirais |
| US20050209245A1 (en) * | 2004-03-19 | 2005-09-22 | Wyeth | Process for preparing N-aryl-piperazine derivatives |
| US20050215561A1 (en) * | 2004-03-19 | 2005-09-29 | Krishnendu Ghosh | Pharmaceutical dosage forms and compositions |
| US20070099931A1 (en) * | 2004-03-19 | 2007-05-03 | Wyeth | Pharmaceutical dosage forms and compositions |
| TW200700413A (en) * | 2005-03-01 | 2007-01-01 | Wyeth Corp | Crystalline and amorphous 4-cyano-n-{(2r)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-propyl}-n-pyridin-2-yl-benzamide hydrochloride |
| AU2011225122B8 (en) * | 2010-03-12 | 2013-12-12 | Nippon Soda Co., Ltd. | Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative |
| EP2602248A1 (en) | 2011-12-05 | 2013-06-12 | University Of Leicester | Novel pyrrole compounds |
| GB201310126D0 (en) * | 2013-06-06 | 2013-07-24 | Univ Leicester | Novel pyrrole derivatives |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0189612B1 (en) | 1984-12-21 | 1992-11-04 | Duphar International Research B.V | New pharmaceutical compositions having a psychotropic activity |
| JPH01125357A (ja) | 1987-11-06 | 1989-05-17 | Dainippon Pharmaceut Co Ltd | トリペプチドの誘導体 |
| MX9201991A (es) | 1991-05-02 | 1992-11-01 | Jonh Wyeth & Brother Limited | Derivados de piperazina y procedimiento para su preparacion. |
| WO1994024115A1 (fr) | 1993-04-16 | 1994-10-27 | Santen Pharmaceutical Co., Ltd. | Nouveau derive de piperazine |
| RU2118322C1 (ru) * | 1993-07-05 | 1998-08-27 | Дюфар Интернэшнл Рисерч Б.В. | 2,3-дигидро-1,4-бензодиокси-5-ил-пиперазиновые производные или их соли |
| GB9411099D0 (en) | 1994-06-03 | 1994-07-27 | Wyeth John & Brother Ltd | Piperazine derivatives |
| JPH10504275A (ja) * | 1994-06-03 | 1998-04-28 | ジョン・ワイス・アンド・ブラザー・リミテッド | ピペラジン誘導体を製造するための新規な方法および中間体 |
| GB9514901D0 (en) * | 1995-07-20 | 1995-09-20 | American Home Prod | Piperazine derivatives |
| JP2000508319A (ja) | 1996-04-10 | 2000-07-04 | メルク エンド カンパニー インコーポレーテッド | αｖβ３拮抗薬 |
| ES2329122T3 (es) * | 2002-03-12 | 2009-11-23 | Wyeth | Procedimiento para sintetizar n-aril piperazinas quirales. |
| JP4397693B2 (ja) | 2002-03-12 | 2010-01-13 | ワイス | Ｎ１−（２’−ピリジル）−１，２−アルカンジアミンスルファミン酸の合成および生物学的に活性なピペラジンの合成におけるその使用 |
-
2003
- 2003-03-10 JP JP2003576402A patent/JP4397693B2/ja not_active Expired - Fee Related
- 2003-03-10 ES ES07007755T patent/ES2334836T3/es not_active Expired - Lifetime
- 2003-03-10 IL IL16382903A patent/IL163829A0/xx unknown
- 2003-03-10 BR BR0308315-2A patent/BR0308315A/pt not_active IP Right Cessation
- 2003-03-10 CN CNB038058421A patent/CN100341854C/zh not_active Expired - Fee Related
- 2003-03-10 RU RU2004130314/04A patent/RU2314294C2/ru not_active IP Right Cessation
- 2003-03-10 EP EP03716415A patent/EP1483243B1/en not_active Expired - Lifetime
- 2003-03-10 DK DK03716415T patent/DK1483243T3/da active
- 2003-03-10 AU AU2003220122A patent/AU2003220122A1/en not_active Abandoned
- 2003-03-10 DE DE60330199T patent/DE60330199D1/de not_active Expired - Lifetime
- 2003-03-10 PT PT03716415T patent/PT1483243E/pt unknown
- 2003-03-10 SI SI200330817T patent/SI1483243T1/sl unknown
- 2003-03-10 TW TW092105099A patent/TWI288642B/zh not_active IP Right Cessation
- 2003-03-10 AT AT03716415T patent/ATE360002T1/de not_active IP Right Cessation
- 2003-03-10 WO PCT/US2003/007228 patent/WO2003078396A1/en not_active Ceased
- 2003-03-10 KR KR10-2004-7014252A patent/KR20040091720A/ko not_active Abandoned
- 2003-03-10 EP EP07007755A patent/EP1801103B1/en not_active Expired - Lifetime
- 2003-03-10 DE DE60313301T patent/DE60313301T2/de not_active Expired - Lifetime
- 2003-03-10 NZ NZ535170A patent/NZ535170A/xx unknown
- 2003-03-10 MX MXPA04008731A patent/MXPA04008731A/es active IP Right Grant
- 2003-03-10 ES ES03716415T patent/ES2283762T3/es not_active Expired - Lifetime
- 2003-03-10 AT AT07007755T patent/ATE449073T1/de not_active IP Right Cessation
- 2003-03-10 US US10/385,337 patent/US6784294B2/en not_active Expired - Fee Related
- 2003-03-10 CA CA002477886A patent/CA2477886A1/en not_active Abandoned
- 2003-03-11 AR ARP030100833A patent/AR038932A1/es unknown
- 2003-10-03 UA UA20041008214A patent/UA80272C2/uk unknown
-
2004
- 2004-09-10 EC EC2004005291A patent/ECSP045291A/es unknown
- 2004-09-24 NO NO20044049A patent/NO20044049L/no not_active Application Discontinuation
- 2004-10-11 ZA ZA200408213A patent/ZA200408213B/en unknown
-
2007
- 2007-06-26 CY CY20071100843T patent/CY1106677T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0206433A (pt) | Composto, composição farmacêutica, processo para a prepapação de um composto, e, uso de um composto | |
| CY1106677T1 (el) | Παρασκευη ν1-(2’-πυριδυλ)-1, 2-προπανοδιαμινο σουλφαμικου οξεος και χρηση αυτου στη συνθεση βιολογικως δραστικων πιπεραζινων | |
| AR048741A1 (es) | Derivados de omega-carboxiaril difenil urea sustituida | |
| BR0307351A (pt) | Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto | |
| AR077414A2 (es) | Compuestos de piperazina como antagonistas de taquinina sus sales y solvatos composiciones farmaceuticas que lo contienen su uso y procesos para su preparacion | |
| ECSP055746A (es) | Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos | |
| ECSP055747A (es) | Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos | |
| BR122012009534B8 (pt) | 4-[2-(4-metil-fenil-sulfanil)-fenil]-piperidina, seu uso e composição farmacêutica compreendendo o referido composto | |
| BRPI0408347B8 (pt) | derivados de pirimidina, seu uso, e composição e combinação farmacêuticas | |
| UY28014A1 (es) | Compuestos quimicos | |
| AR024390A1 (es) | Nuevos compuestos | |
| ES8201948A1 (es) | Un procedimiento para la preparacion de nuevos derivados transisomericos de 4-fenil-1,2,3,4- tetrahidro-1-naftalenamina. | |
| ECSP055671A (es) | Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa | |
| ATE327229T1 (de) | Verbindungen und deren verwendung als 5-ht inhibitore | |
| AR010080A1 (es) | Derivados de 1,2,3,4-tetrahidronaftaleno | |
| UY28528A1 (es) | Nuevos compuestos | |
| NO20054787L (no) | Indenderivater som farmasotiske midler | |
| UY26656A1 (es) | "metabolitos agonistas/antagonistas de estrogeno" | |
| AR044453A1 (es) | Derivados de metoxi-pirazin-tienil sulfonamida | |
| BRPI0411308A8 (pt) | Composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto | |
| AR034206A1 (es) | Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos | |
| CO5590934A2 (es) | Procedimiento de preparacion de derivados de equinocandina | |
| EA200100040A1 (ru) | Химический синтез морфолиновых производных | |
| AR028743A1 (es) | DERIVADOS DE N-TRIAZOLILMETIL-PIPERAZINA CON ACCIoN ANTAGONISTA DE RECEPTORES DE NEUROQUININA | |
| BR0309668A (pt) | Imidazolinilmetil aralquilsulfonamidas |